MorphoSys has been granted a patent for novel compounds and pharmaceutical compositions for treating diseases related to methyl modifying enzymes. The compounds of Formula (I) and their salts are claimed for use in various conditions. GlobalData’s report on MorphoSys gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MorphoSys AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MorphoSys, Personalized cancer vaccines was a key innovation area identified from patents. MorphoSys's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11919912B2) discloses a compound of a specific chemical formula, along with various derivatives and configurations of the compound. The compound is described with specific substituents denoted by R1, R4, R5, and R6, which can be halo or alkyl groups. Additionally, the patent includes details about the stereochemical configuration of the compound, specifying the chiral center of the 1,3-dioxolanyl group as either R or S. The patent also covers pharmaceutical compositions containing the compound and its pharmaceutically acceptable salts, along with a carrier, for potential use in treating cancer.

Furthermore, the patent outlines a method for treating cancer in a subject by administering an effective amount of the compound or its pharmaceutically acceptable salt. The types of cancer that can be targeted using this method include breast cancer, prostate cancer, colon cancer, renal cell carcinoma, glioblastoma multiforme cancer, bladder cancer, melanoma, and various others. This patent provides a detailed insight into the chemical composition, potential therapeutic applications, and treatment methods involving the disclosed compound, offering a valuable contribution to the field of oncology research and drug development.

To know more about GlobalData’s detailed insights on MorphoSys, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies